Technology
Juveena® is an advanced therapy designed specifically for the prevention of the formation and reformation of intrauterine adhesions (IUAs).
ELEVATING UTERINE HEALTH

About the Juveena® Hydrogel System

Prevent IUAs

The Juveena Hydrogel System (HS), is intended for use as a temporary implant to prevent the formation or reformation of intrauterine adhesions (IUAs) following transcervical gynecological procedures.

Proprietary

The Juveena Hydrogel System consists of a proprietary transcervical catheter and two liquid precursors that fill the uterine cavity and immediately cross-link to form a soft temporary hydrogel implant that separates the uterine walls and prevent intrauterine adhesions from forming during the healing process.

The Juveena Hydrogel System in Pending FDA Approval. Not Available For Sale. Investigation Use Only.
KEY BENEFITS / EFFECTIVE PREVENTION

Juveena is intended to prevent the formation of IUAs, addressing a critical concern for both physicians and their patient.

Innovative Delivery System
The low-profile, transcervical catheter ensures accurate placement and comfort for the patient
Healing Support
The hydrogel conforms to the uterine cavity and remains in place to create a favorable environment for the uterine lining to heal by providing both space and time for recovery.
Water-based Technology
The composition of the hydrogel is designed to liquify after 2-3 weeks (or one menstrual cycle) therefore no secondary follow-up procedure needed for removal.
Increased Confidence
Clinicians and women can trust using Juveena after transcervical procedures to reduce the risk of developing  IUAs. Juveena has been clinically evaluated in women with moderate to severe adhesions or who had fibroids removed.
The Juveena Hydrogel System in Pending FDA Approval. Not Available For Sale. Investigation Use Only.
What are intrauterine adhesions(IUAs)?
Intrauterine Adhesions (IUAs), happen when scar tissue forms inside the uterus or cervix.1-3 This can occur after an injury to the uterus, such as surgery or a complicated pregnancy, which causes the lining to heal with bands of tissue. These adhesions can be thin or thick and may cover small or large areas. Doctors classify IUAs as mild, moderate, or severe based on how much scar tissue is present.
The Juveena Hydrogel System in Pending FDA Approval. Not Available For Sale. Investigation Use Only.
IUAs often happen after procedures like dilation and curettage (D&C),which may be done for:
Elective pregnancy termination
Treatment of a miscarriage
Removal of a retained placenta after delivery
IUAs can also develop after surgery for:
Fibroid removal
Excessive uterine bleeding3,4
Endometrial cancer testing
Uterine Septums
Repeat adhesion removal
The Juveena Hydrogel System in Pending FDA Approval. Not Available For Sale. Investigation Use Only.
INTRAUTERINE ADHESIONS: CAUSES, RISKS, AND PREVALENCE

How Common Are IUAs?

IUAs often go unnoticed, especially in women who are not trying to conceive. Symptoms include lighter-than-normal periods (hypomenorrhea) or no periods at all. Standard exams and ultrasounds may not detect IUAs, leading to underdiagnosis.

IUAs and Pregnancy
after a late miscarriage
in women needing follow-up surgery after delivery or miscarriage
of women after a first-trimester pregnancy termination
IUAs and Pregnancy
after the second hysteroscopic resection
after the first hysteroscopic resection
The Juveena Hydrogel System in Pending FDA Approval. Not Available For Sale. Investigation Use Only.

Who Is at Higher Risk?

Women with placental abnormalities, such as Placenta Accreta, are at greater risk because the placenta attaches more deeply to the uterus, making it harder to remove.4,5

Repeated procedures, including multiple D&Cs, also increase the likelihood of developing IUAs.

Higher risk with multiple surgeries
Placental abnormalities increase the chance of IUAs
The Juveena Hydrogel System in Pending FDA Approval. Not Available For Sale. Investigation Use Only.
Scientific Publications

Why Juveena

Cost Effectiveness Publication

Presentation/Abstracts/Posters

Bhagavath et al
Munro et al
Garza Leal
Munro et al
Salazar et al
ISPOR-2025
UTERINE ADHESION RESOURCES

Patient and Physician Communities

The Juveena Hydrogel System in Pending FDA Approval. Not Available For Sale. Investigation Use Only.
  1. Queckbörner S, Davies LC, von Grothusen C, Santamaria X, Simón C, Gemzell-Danielsson K. Cellular therapies for the endometrium: An update. Acta Obstet Gynecol Scand. 2019 May;98(5):672-677. [PubMed]
  2. Guo EJ, Chung JPW, Poon LCY, Li TC. Reproductive outcomes after surgical treatment of asherman syndrome: A systematic review. Best Pract Res Clin Obstet Gynaecol. 2019 Aug;59:98-114. [PubMed]
  3. Ludwin A, Martins WP, Ludwin I. Ultrasound-guided repeat intrauterine balloon dilatation for prevention of adhesions. Ultrasound Obstet Gynecol. 2019 Oct;54(4):566-568. [PubMed]
  4. Chikazawa K, Imai K, Liangcheng W, Sasaki S, Horiuchi I, Kuwata T, Takagi K. Detection ofAsherman's syndrome after conservative management of placenta accreta: a case report. J Med Case Rep. 2018 Nov20;12(1):344. [PMC free article] [PubMed]
  5. Tchente NC, Brichant G, Nisolle M. [Asherman's syndrome : management after curettage following a postnatal placental retention and literature review].  Rev Med Liege. 2018 Oct;73(10):508-512. [PubMed]
The Juveena Hydrogel System in Pending FDA Approval. Not Available For Sale. Investigation Use Only.
Copyright © 2026 Rejoni. All Rights Reserved. These statements have not been evaluated by the Food and Drug Administration.
CAUTION – Limited by Federal (USA) Law to Investigational Use Only. REJ-MKT-0024-Rev. B
Privacy Statement